Nowadays virus-like particles (VLPs) have become a widely used vehicle for the development of vaccines used in humans. Without being infectious, the particles are used to transport foreign antigens in an ideal way to the immune system. For veterinary applications, the applied VLP production process needs to be simplified and optimized. The platform technology and the common production process requires adaption in reference to cost-effectiveness and promptness. Especially the factor “manufacturing cost” is the major driver for a successful market introduction and will influence the acceptance for later necessary mass vaccinations in the veterinary field.
The intent of “Plurivax” is to develop a stable production platform and an adapted high-quality process to have an effective and usable integrated best practice suitable for several veterinary vaccines.
The platform resulting from this project will be the first of its kind in veterinary application and thus opens access to a huge market. A robust, inexpensive vaccine will reduce the need for antibiotic treatment of food animals, thereby directly reducing production costs and improving quality of life for the food animal itself and for the consumer.
“ARTES VLP platform METAVAX® has already been applied to the development of adjuvant-free vaccines against different diseases like avian and swine flu, malaria and HIV. Our yeast expression host Hansenula is the preferred technology for affordable mass vaccination and is recommended by the WHO for mass vaccinations. Together, our platforms build an excellent approach to low-cost mass production of safe and effective vaccines”, Michael Piontek, Managing Director of ARTES.
Annie Van Broekhoven, CEO Q-Biologicals comments: “We will employ our know-how and expertise in the field of bioprocess development, manufacturing and formulation of recombinant antigens to develop a robust production process for VLP based vaccines. Our aim is to generate a generic, low-cost manufacturing process which will result in a high yield of a stable vaccine. Levering our expertise in production of recombinant antigens, we are confident that we will succeed in shortening the process development times considerably, and in doing so drive down development costs and support rapid market introduction.”
“We at instrAction will contribute our tailor made but competitively priced platform purification process to this cost sensitive production processes. Our proprietary chromatography phase technology, already being used for purification of commercial biopharmaceuticals and small molecule APIs, allows specific binding of target molecules whether impurity or API, and can be transferred to almost every chromatographic carrier substrate to enable optimum separation and process robustness.”, Peter Kallien, CFO of instrAction, pointed out.